ADC Therapeutics SA
ADCT
$1.89
$0.2011.83%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.49% | 1.84% | -42.30% | -63.80% | -62.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.49% | 1.84% | -42.30% | -63.80% | -62.38% |
| Cost of Revenue | -13.04% | -11.36% | 95.43% | 25.93% | 14.43% |
| Gross Profit | 30.61% | 21.74% | -294.89% | -238.92% | -317.96% |
| SG&A Expenses | -15.70% | -18.87% | -21.12% | -27.12% | -28.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.65% | -14.46% | -19.35% | -28.59% | -30.92% |
| Operating Income | 15.99% | 21.29% | -1.27% | -34.18% | -12.16% |
| Income Before Tax | 20.61% | 21.53% | 7.18% | 7.85% | 4.75% |
| Income Tax Expenses | -99.57% | -99.58% | 4,422.57% | 2,757.89% | 1,923.55% |
| Earnings from Continuing Operations | 34.07% | 34.25% | -17.53% | -16.55% | -13.73% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.07% | 34.25% | -17.53% | -16.55% | -13.73% |
| EBIT | 15.99% | 21.29% | -1.27% | -34.18% | -12.16% |
| EBITDA | 16.18% | 21.53% | -1.10% | -34.27% | -12.10% |
| EPS Basic | 47.48% | 43.56% | -8.08% | -10.88% | -9.16% |
| Normalized Basic EPS | 36.79% | 32.76% | 16.24% | -13.46% | -16.33% |
| EPS Diluted | 47.48% | 43.56% | -8.08% | -10.88% | -9.16% |
| Normalized Diluted EPS | 36.79% | 32.76% | 16.24% | -13.46% | -16.33% |
| Average Basic Shares Outstanding | 25.73% | 18.86% | 12.42% | 6.75% | 3.80% |
| Average Diluted Shares Outstanding | 25.73% | 18.86% | 12.42% | 6.75% | 3.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |